gp130 Activators
The chemical class of gp130 activators encompasses a diverse array of compounds that intricately modulate the signaling pathways associated with gp130 activation. These compounds, spanning kinase inhibitors, multi-kinase inhibitors, and pathway modulators, collectively exert their influence on gp130 by targeting various cellular processes. Stattic, for instance, directly inhibits STAT3, a downstream effector of gp130 signaling, disrupting the negative feedback loop and promoting gp130 activation. Ruxolitinib, a JAK1/2 inhibitor, indirectly activates gp130 by preventing the phosphorylation of STAT proteins, thereby relieving negative regulation on gp130.
Sorafenib, a multi-kinase inhibitor, indirectly activates gp130 by disrupting the RAF/MEK/ERK pathway. This interference alleviates negative feedback on gp130, amplifying its phosphorylation and activation. These examples underscore the complexity of gp130 activation regulation and the diverse mechanisms employed by these chemicals to influence cellular pathways. Niclosamide, another gp130 activator, indirectly modulates gp130 by influencing the Wnt/β-catenin pathway. By inhibiting Wnt signaling, Niclosamide disrupts crosstalk between Wnt and gp130 pathways, leading to enhanced gp130 activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor that indirectly influences gp130 activation. JAKs are upstream kinases in the gp130 signaling pathway. Inhibition of JAK1/2 by Ruxolitinib disrupts the phosphorylation of STAT proteins, including STAT3, preventing the negative regulation of gp130 and allowing for sustained activation of gp130-mediated signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly activates gp130 by inhibiting the RAF/MEK/ERK pathway. By blocking RAF, Sorafenib disrupts downstream signaling pathways, relieving negative feedback on gp130 activation. This indirect mechanism enhances the phosphorylation and activation of gp130, promoting its role in cellular processes. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide indirectly activates gp130 by modulating the Wnt/β-catenin pathway. Through inhibition of Wnt signaling, Niclosamide disrupts the negative crosstalk between Wnt and gp130 pathways, leading to enhanced gp130 activation. The intricate interplay between these pathways highlights the indirect regulatory role of Niclosamide in gp130-mediated cellular responses. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces gp130 activation indirectly by causing DNA damage and activating the p53 pathway. The activated p53 pathway enhances the expression of gp130, amplifying its availability for activation and subsequent signaling. This indirect modulation underscores the intricate interconnections between DNA damage response pathways and gp130-mediated cellular processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a dual BCR-ABL/Src family kinase inhibitor, indirectly activates gp130 by modulating Src kinases. By inhibiting Src, Dasatinib disrupts negative regulation on gp130, facilitating its phosphorylation and activation. This indirect influence emphasizes the role of Src kinases in regulating gp130 signaling and their potential as therapeutic targets for modulating gp130 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib indirectly activates gp130 by inhibiting the NF-κB pathway. By blocking the proteasome, Bortezomib prevents the degradation of IκB, leading to the inhibition of NF-κB and relieving negative regulation on gp130. This indirect influence underscores the crosstalk between NF-κB signaling and gp130 activation, revealing a novel regulatory axis in the control of gp130-mediated cellular responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that indirectly activates gp130 by modulating the MAPK pathway. Inhibition of p38 MAPK by SB203580 disrupts the negative regulation on gp130, promoting its activation. This indirect influence highlights the intricate regulatory network involving p38 MAPK and gp130 signaling, emphasizing the potential of p38 MAPK inhibitors in modulating gp130-mediated cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 indirectly activates gp130 by inhibiting the PI3K/Akt pathway. By blocking PI3K, LY294002 disrupts the negative regulation on gp130, enhancing its phosphorylation and activation. This indirect modulation reveals the interplay between PI3K/Akt signaling and gp130 activation, providing insights into potential therapeutic strategies for manipulating gp130 activity in various cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin indirectly activates gp130 by inhibiting the mTOR pathway. By blocking mTOR, Rapamycin disrupts the negative regulation on gp130, promoting its phosphorylation and activation. This indirect influence highlights the intricate connections between mTOR signaling and gp130 activation, suggesting potential avenues for therapeutic intervention in diseases where dysregulated gp130 activity plays a role. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly activates gp130 by modulating the MAPK pathway. Inhibition of MEK by Trametinib disrupts the negative regulation on gp130, promoting its activation. This indirect modulation emphasizes the regulatory role of the MAPK pathway in governing gp130 activity, offering insights into potential therapeutic strategies for manipulating gp130 in diseases where aberrant MAPK signaling is implicated. | ||||||